Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Omnicom Group Inc. — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.43 (market cap $6.04B), while Omnicom Group Inc. trades at $76.35 (market cap $20.97B). The key difference: Omnicom Group Inc. is far larger — about 3.5× Iovance Biotherapeutics Inc. Common Stock's market cap, and Omnicom Group Inc. pays a 4.19% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Omnicom Group Inc. for 63 Days on average.
| IOVA | OMC | |
|---|---|---|
Market Cap | $6.04B | $20.97B |
Volume | 14,805,993 | 2,092,899 |
Sector | Health | Media |
52-Week High | $14.82 | $88.94 |
52-Week Low | $1.81 | $67.27 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $5.97B | $29.05B |
Dividend Yield | — | 4.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Omnicom Group (OMC) trades at $74.87, down 0.31% on the day, with a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $17.27B in 2025 but posted a net loss of -$54.50M due to elevated expenses. Recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings. Valuation metrics show a high P/E of 202.35 but attractive P/S of 0.84, while analyst consensus is mixed with a $104.67 price target.
OMC presents a value opportunity with its low P/S ratio and 4.2% dividend yield, offset by profitability concerns and high debt. The stock's 39% discount to consensus target suggests upside if margin improvements materialize from recent acquisitions. Key risks include advertising market volatility and integration challenges from the Interpublic deal. Institutional activity shows mixed positioning with recent trimming by major banks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
